Analysts Anticipate Revance Therapeutics, Inc. (RVNC) Will Announce Quarterly Sales of $80,000.00
Analysts forecast that Revance Therapeutics, Inc. (NASDAQ:RVNC) will post $80,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Revance Therapeutics’ earnings. Revance Therapeutics also posted sales of $80,000.00 during the same quarter last year. The company is scheduled to report its next earnings results on Monday, February 26th.
According to Zacks, analysts expect that Revance Therapeutics will report full year sales of $80,000.00 for the current year, with estimates ranging from $300,000.00 to $400,000.00. For the next year, analysts expect that the company will report sales of $400,000.00 per share, with estimates ranging from $200,000.00 to $600,000.00. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Revance Therapeutics.
Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.06). Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. During the same period in the prior year, the firm earned ($0.64) EPS. The business’s quarterly revenue was up .0% on a year-over-year basis.
Several equities analysts recently commented on RVNC shares. Zacks Investment Research raised shares of Revance Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research report on Tuesday, August 22nd. Piper Jaffray Companies set a $28.00 price target on shares of Revance Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $50.00 price target on shares of Revance Therapeutics in a research report on Wednesday, September 6th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Revance Therapeutics has a consensus rating of “Buy” and a consensus target price of $35.20.
TRADEMARK VIOLATION NOTICE: “Analysts Anticipate Revance Therapeutics, Inc. (RVNC) Will Announce Quarterly Sales of $80,000.00” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/analysts-anticipate-revance-therapeutics-inc-rvnc-will-announce-quarterly-sales-of-80000-00/1690603.html.
Shares of Revance Therapeutics (NASDAQ RVNC) traded down $0.90 during mid-day trading on Thursday, reaching $25.40. 39,803 shares of the company traded hands, compared to its average volume of 133,903. Revance Therapeutics has a 1 year low of $13.05 and a 1 year high of $28.75.
In other news, CEO L Daniel Browne sold 22,800 shares of the company’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $22.76, for a total value of $518,928.00. Following the completion of the transaction, the chief executive officer now directly owns 178,850 shares in the company, valued at $4,070,626. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Lauren P. Silvernail sold 11,164 shares of the company’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $26.67, for a total transaction of $297,743.88. The disclosure for this sale can be found here. Insiders sold 49,226 shares of company stock valued at $1,196,318 in the last three months. Company insiders own 18.86% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Ameriprise Financial Inc. boosted its stake in Revance Therapeutics by 1.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,904 shares of the biopharmaceutical company’s stock valued at $604,000 after acquiring an additional 225 shares during the last quarter. Legal & General Group Plc boosted its stake in Revance Therapeutics by 8.1% during the 2nd quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock valued at $152,000 after acquiring an additional 438 shares during the last quarter. American International Group Inc. boosted its stake in Revance Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 834 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Revance Therapeutics by 7.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,304 shares of the biopharmaceutical company’s stock valued at $483,000 after acquiring an additional 1,275 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its holdings in shares of Revance Therapeutics by 5.9% during the first quarter. Parametric Portfolio Associates LLC now owns 27,401 shares of the biopharmaceutical company’s stock worth $570,000 after purchasing an additional 1,524 shares during the period. Hedge funds and other institutional investors own 89.32% of the company’s stock.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.